65,437 trials
Low Back Pain
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 70; 63; 67; 8 Participants
COPD Exacerbation
Primary: Dyspnea Intensity — 8.0; 6.5; 7.75; 5 units on a scale
Contraception
Primary: Serum Etonogestrel (ENG) Level — 243.3 pg/mL
Acute Otitis Media
Primary: Number of Participants With Adverse Events — 48; 36 Participants
Diabetes
Primary: Change in Glucose Disposition — 1.18; 1.42 ratio of post/pre values — p=0.042
Lymphoma, Non-Hodgkin
Primary: Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in First Cycle in Caucasian Patients — 100 Milligram (mg)
Cancer-related Problem/Condition · Depression · Circadian Rhythm Disorders
Primary: FACIT-Fatigue Scale — 37.00; 35.06; 38.71; 35.00 score on a scale
Alzheimer's Disease
Primary: Urine Analysis - Total Integrated Radioactivity Excreted in Urine — 0.1413 megabecquerel-hours per megabecquerel
Migraine
Primary: Number of Participants Who Achieve Freedom From Headache — 4; 0 Participants
Chronic Insomnia
Primary: Insomnia Severity Index (ISI) — 9.6; 11.0 score on a scale — p=<0.05
Alzheimer Disease
Primary: Primary Objective 1 Analysis 1: Diagnostic Performance of Individual Readers (NFT Score) — 91.5; 77.1; 89.4; 91.4 percentage of cases correctly identified
Adult Liposarcoma · Metastatic Liposarcoma · Metastatic Osteosarcoma
Primary: Progression Free Survival at 12 Weeks for Patients With Soft Tissue Sarcoma (STS) Treated With Pazopanib and Oral Topotecan — 57.5 percentage of patients progression free
Cataract Bilateral · Presbyopia
Primary: Binocular Uncorrected Near (40 cm) Visual Acuity. — 0.13 logMAR
Opioid Use Disorder
Primary: Recruitment Rate — 76; NA; NA; 71 Participants
COPD Exacerbation
Primary: Adherence to One Balance Practice Routine — 49 percentage of participants